Potential new malaria vaccine shows promise in Burkina Faso trial
The Hindu
The candidate vaccine, developed by scientists at Oxford University showed up to 77% efficacy
A potential new malaria vaccine has proved highly effective in a trial in babies in Africa, pointing to it one day possibly helping reduce the death toll from the mosquito-born disease that kills up to half a million young children a year. The candidate vaccine, developed by scientists at Britain's University of Oxford and called R21/Matrix-M, showed up to 77% efficacy in the year-long trial of 450 children in Burkina Faso,researchers leading the trial said in a statement. The scientists, led by Adrian Hill, director of Oxford's Jenner Institute and also one of the lead researchers behind the Oxford-AstraZeneca COVID-19 vaccine, said they now plan to conduct final stage trials in some 4,800 children aged between 5months and 3 years in four African Countries.More Related News
EU and Israel in war of words as ties nosedive ahead of Spain, Ireland recognizing Palestinian state
EU-Israel relations strained over Palestinian state recognition, with threats of sanctions and ICC involvement in conflict.